DOUBLE-ACTION PHARMACEUTICAL COMPOSITIONS OF SUBMOLECULAR STRUCTURE OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) AND NEUTRAL ENDOPEPTIDASE (NEP) INHIBITOR Russian patent published in 2013 - IPC A61K31/216 A61K31/41 A61K9/20 A61J3/10 A61P9/00 A61P9/10 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a solid oral dosage form for the delivery of a therapeutically effective amount of valsartan in the form of a free acid or a pharmaceutically acceptable salt thereof. The dosage form contains a double-action compound in the amount of 4 to 90 % at composition weight, and pharmaceutically acceptable excipients. The double-action compound is trisodium salt [3-((1S3R)^_1^_biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl)propionate-(S)-3'-methyl-2'-(pentanoyl{2"-tetrazol-5-ylate)biphenyl-4'-ylmethyl}amino)butyric acid] hemipentahydrate. The above double-action compound is found in one standard dosage form in the amount of 40, 50, 100, 200 or 400 mg. Also, the invention refers to a method for preparing a solid oral dosage forms. The dosage form according to the invention is characterized by a solution profile in vitro such that 30 min later approximately 10 to approximately 100 wt % of valsartan in average is released in the form of a free acid or a pharmaceutically acceptable salt thereof.

EFFECT: specified valsartan solution profile and absorption rate provide a lower dosage of valsartan.

15 cl, 3 dwg, 6 tbl, 6 ex